We are live on ! Find out more
IGC icon

IGC Pharma
IGC

6 hedge funds and large institutions have $78K invested in IGC Pharma in 2017 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% less funds holding

Funds holding: 9 → 6 (-3)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

65% less capital invested

Capital invested by funds: $223K → $78K (-$145K)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

Holders
6
Holders Change
-3
Holders Change %
-33.33%
% of All Funds
0.15%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
2
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
+$6.4K
2
Citadel Advisors
Citadel Advisors
Florida
+$3.2K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$15.5K
2
PAM
Panagora Asset Management
Massachusetts
-$6.22K
3
Bank of New York Mellon
Bank of New York Mellon
New York
-$4K
4
Deutsche Bank
Deutsche Bank
Germany
-$4K
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
PAM
1
Panagora Asset Management
Massachusetts
$27K -$6.22K -16,793 -18%
Creative Planning
2
Creative Planning
Kansas
$21K – – –
Citadel Advisors
3
Citadel Advisors
Florida
$12K +$3.2K +8,628 +36%
UBS Group
4
UBS Group
Switzerland
$11K -$15.5K -41,884 -58%
VF
5
Virtu Financial
New York
$6K +$6.4K +17,286 New
LTFS
6
Ladenburg Thalmann Financial Services
Florida
$1K – – –
Deutsche Bank
7
Deutsche Bank
Germany
– -$4K -11,475 Closed
Bank of New York Mellon
8
Bank of New York Mellon
New York
– -$4K -10,000 Closed
Acadian Asset Management
9
Acadian Asset Management
Massachusetts
– -$1K -2,876 Closed

IGC Hedge Fund Activity: Q3 2017 in Review

6 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q3 2017, worth a combined $78K — down 65% from $223K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of IGC and 1 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 1 added.

The largest buyer was Virtu Financial, opening a new position worth an estimated $6.4K. The largest seller was UBS Group, cutting an estimated $15.5K.

  • 6 institutional investors held IGC Pharma (IGC) as of Q3 2017, down from 9 in Q2 2017.
  • Funds reported $78K of IGC Pharma stock for Q3 2017, down 65% quarter-over-quarter.
  • 1 fund opened new IGC Pharma positions in Q3 2017 and 3 closed out, a net change of -2 holders.
  • The largest IGC Pharma buyer in Q3 2017 was Virtu Financial, an estimated $6.4K added.
  • The largest IGC Pharma seller in Q3 2017 was UBS Group, an estimated $15.5K sold.

Based on aggregated 13F filings for Q3 2017.